Alto Neuroscience (ANRO) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alto Neuroscience (ANRO) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 296.0% versus a gain of 16.1%. Alto Neuroscience is the larger company by market cap ($923.0 million vs $916.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANRO | MLTX |
|---|---|---|
| Share price | $23.52 | $10.77 |
| Market cap | $922.97M | $916.60M |
| 1-day change | -0.72% | -1.64% |
| YTD return | +32.13% | -18.29% |
| 1-year return | +295.96% | +16.06% |
| 5-year return | — | +8.57% |
| EPS (TTM) | $-2.31 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.48 | $23.29 |
| 52-week low | $5.23 | $8.80 |
| Distance from 52-week high | -37.25% | -53.76% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +63.18% | +165.00% |
| Average volume | 543.14K | 1.44M |
| Shares outstanding | 39.24M | 85.11M |
| Employees | 68 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANRO has outperformed MLTX by 279.9 percentage points over the past year.
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
ANRO vs MLTX FAQ
Which is bigger, Alto Neuroscience or MoonLake Immunotherapeutics?
Alto Neuroscience (ANRO) is larger, with a market capitalization of $922.97M compared with $916.60M for MoonLake Immunotherapeutics (MLTX).
Which stock has performed better over the past year, ANRO or MLTX?
ANRO returned +295.96% over the past 12 months, compared with +16.06% for MLTX (price return, excluding dividends). Past performance does not predict future results.
Are Alto Neuroscience and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.